Maturitas
Volume 54, Issue 2 , Pages 164-175 , 20 May 2006

A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts

  • Arne Heyerick

      Affiliations

    • Laboratory of Pharmacognosy and Phytochemistry, Ghent University-UGent, Harelbekestraat 72, 9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 9 264 8059; fax: +32 9 264 8192.
    • ,
  • Stefaan Vervarcke

      Affiliations

    • Biodynamics, J. Plateaustraat 4, 8400 Ostend, Belgium
    • ,
  • Herman Depypere

      Affiliations

    • Department of Gynaecological Oncology, Ghent University Hospital, De Pintelaan 135, 9000 Ghent, Belgium
    • ,
  • Marc Bracke

      Affiliations

    • Department of Radiotherapy and Clinical Oncology, Ghent University Hospital, De Pintelaan 135, 9000 Ghent, Belgium
    • ,
  • Denis De Keukeleire

      Affiliations

    • Laboratory of Pharmacognosy and Phytochemistry, Ghent University-UGent, Harelbekestraat 72, 9000 Ghent, Belgium

Received 4 February 2005 ,Revised 10 October 2005 ,Accepted 11 October 2005.

References 

  1. van der Mooren MJ, Kenemans P. Postmenopausal hormone therapy - Impact on menopause-related symptoms, chronic disease and quality of life. Drugs. 2004;64:821–836
  2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  5. Naftolin F, Schneider HPG, Sturdee DW, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric. 2004;7:333–337
  6. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. New Engl J Med. 2001;345:1243–1249
  7. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New Engl J Med. 2003;349:535–545
  8. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17 beta-estradiol and bone density and bone metabolism in older women - A randomized controlled trial. JAMA. 2003;290:1042–1048
  9. Santoro NF, Clarkson TB, Freedman RR, Fugh-Berman AJ, Loprinzi CL, Reame NK. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11–33
  10. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: Recent developments. Planta Med. 2003;69:589–599
  11. Milligan SR, Kalita JC, Heyerick A, Rong H, De Cooman L, De Keukeleire D. Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J Clin Endocrinol Metab. 1999;84:2249–2252
  12. Milligan SR, Kalita JC, Pocock V, et al. The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J Clin Endocrinol Metab. 2000;85:4912–4915
  13. Milligan S, Kalita J, Pocock V, et al. Oestrogenic activity of the hop phyto-oestrogen, 8-prenylnaringenin. Reproduction. 2002;123:235–242
  14. Coldham NG, Sauer MJ. Identification, quantitation and biological activity of phytoestrogens in a dietary supplement for breast enhancement. Food Chem Toxicol. 2001;39:1211–1224
  15. Gester S, Metz P, Zierau O, Vollmer G. An efficient synthesis of the potent phytoestrogens 8-prenylnaringenin and 6-(1,1-dimethylallyl)naringenin by europium(III)-catalyzed Claisen rearrangement. Tetrahedron. 2001;57:1015–1018
  16. Zierau O, Gester S, Schwab P, et al. Estrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl) naringenin and 8-prenylnaringenin. Planta Med. 2002;68:449–451
  17. Gerhauser C, Alt A, Heiss E, et al. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther. 2002;1:959–969
  18. Takamura-Enya T, Ishihara J, Tahara S, et al. Analysis of estrogenic activity of foodstuffs and cigarette smoke condensates using a yeast estrogen screening method. Food Chem Toxicol. 2003;41:543–550
  19. Bovee TFH, Helsdingen RJR, Rietjens I, Keijer J, Hoogenboom R. Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004;91:99–109
  20. Schaefer O, Humpel M, Fritzemeier KH, Bohlmann R, Schleuning WD. 8-Prenylnaringenin is a potent ER alpha selective phytoestrogen present in hops and beer. J Steroid Biochem Mol Biol. 2003;84:359–360
  21. Diel P, Thomae RB, Caldarelli A, et al. Regulation of gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats. Planta Med. 2004;70:39–44
  22. Miyamoto M, Matsushita Y, Kiyokawa A, et al. Prenylflavonoids: A new class of non-steroidal phytoestrogen (part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. Planta Med. 1998;64:516–519
  23. Pepper MS, Hazel SJ, Humpel M, Schleuning WD. 8-prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. J Cell Physiol. 2004;199:98–107
  24. Rong HJ, Boterberg T, Maubach J, et al. 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cells. Eur J Cell Biol. 2001;80:580–585
  25. Miranda CL, Yang YH, Henderson MC, et al. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline, mediated by cDNA-expressed human CYP1A2. Drug Metab Dispos. 2000;28:1297–1302
  26. Goetz P. Traitement des bouffées de chaleur par insuffisance ovarienne par l’extrait de houblon (Humulus lupulus). Rev Phytothérapie Pratique. 1990;4:13–15
  27. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol. 1953;13:688–703
  28. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality-of-life questionnaire: Development and psychometric properties. Maturitas. 1996;24:161–175
  29. Rong H, Zhao Y, Lazou K, De Keukeleire D, Milligan SR, Sandra P. Quantitation of 8-prenylnaringenin, a novel phytoestrogen in hops (Humulus lupulus L.), hop products, and beers, by benchtop HPLC-MS using electrospray ionization. Chromatographia. 2000;51:545–552
  30. Alder E. The Blatt-Kupperman menopausal index: a critique. Maturitas. 1998;29:19–24
  31. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2002;9:329–334
  32. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. J Clin Oncol. 2002;20:1449–1455
  33. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality-of-life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: A placebo-controlled study. Menopause. 2003;10:29–36
  34. St Germain A, Peterson CT, Robinson JG, Alekel L. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause. 2001;8:17–26
  35. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91:6–11
  36. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: A pilot study. Menopause. 2000;7:105–111
  37. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000;7:236–242
  38. Murkies AL, Lombard C, Strauss BJG, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases postmenopausal hot flushes - Effect of soy and wheat. Maturitas. 1995;21:189–195
  39. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric. 1998;1:124–129
  40. Setchell KDR, Brown NM, Desai PB, et al. Bioavailability, disposition, and dose–response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr. 2003;133:1027–1035
  41. Setchell KDR, Faughnan MS, Avades T, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of C13-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77:411–419
  42. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol - A clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132:3577–3584

PII: S0378-5122(05)00282-3

doi: 10.1016/j.maturitas.2005.10.005

Maturitas
Volume 54, Issue 2 , Pages 164-175 , 20 May 2006

Article Tools

* Image Usage & Resolution